WHO has taken a major step to address the rapidly growing obesity problem worldwide.
Recommendation to consider the use of drugs
For the first time, the WHO has clearly stated that a new generation of weight loss drugs, GLP-1 therapy, can play an important role in reducing obesity. These drugs include well-known brands such as Ozempic and Monjaro, which have become extremely popular in recent years. According to the WHO, obesity is no longer just a lifestyle issue. But is a chronic and relapsing disease. Therefore, the organization recommends considering the long-term use of GLP-1 drugs for the treatment of obesity in adults.
Appalling levels of obesity
In 2022, more than 37 lakh people died due to obesity or weight-related diseases. This number is more than deaths from malaria, tuberculosis and HIV combined. WHO estimates that if the situation continues. So by 2030, the number of people living with obesity in the world will double. WHO chief Dr. Obesity is a global Health challenge, says Tedros Adhanom. Drugs alone cannot solve this crisis, but GLP-1 therapy can help millions of people lose weight and reduce its associated risks.
What do the experts say?
Endocrinologist Dr. Shaheed Hospital, Raipur. Shailesh Jena says the new WHO guidelines are a step in the right direction. According to him, GLP-1 drugs have shown better results than expected in the treatment of obesity. These drugs control appetite. Improves metabolism and increases insulin sensitivity. Therefore, it can be an important adjunct to patients. whose response to diet and exercise is limited. Dr. According to Shailesh J, obesity is not just a matter of weight gain, but a metabolic disorder that requires long-term management.
Disclaimer: Some of the information given in the news is based on media reports. Sandesh News does not confirm this matter. You should consult a relevant expert before implementing any suggestion.
Also read: World News: Donald Trump may get a blow again, in the mayoral election debate, know what is the matter?
